R Winzenrieth1, M S Ominsky2, Y Wang2, L Humbert1, R J Weiss3. 1. Galgo Medical, Carrer de París, 179 2°, Barcelona, 08036, Spain. 2. Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA. 3. Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA. rweiss@radiuspharm.com.
Abstract
In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. INTRODUCTION: In ACTIVE, abaloparatide (ABL) increased bone mineral density (BMD) shown by dual-energy X-ray absorptiometry (DXA) while reducing fracture incidence in postmenopausal osteoporotic women. Changes in DXA BMD with ABL, 80 μg, were significantly greater than with open-label teriparatide (TPTD), 20 μg, at cortical sites including total hip, femoral neck, and 1/3 distal radius. The purpose of this study was to better understand the relative effects of ABL and TPTD on cortical and cancellous compartments in the proximal femur. METHODS: Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18. RESULTS: Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months. In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD. In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains. CONCLUSION: These results suggest previously reported differences in areal BMD increases between ABL and TPTD may be due to differential effects on cortical vBMD. Further studies are warranted to investigate how these differences affect therapeutic impact on hip strength in postmenopausal women with osteoporosis.
In postmenopausal osteoporoticwomen in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. INTRODUCTION: In ACTIVE, abaloparatide (ABL) increased bone mineral density (BMD) shown by dual-energy X-ray absorptiometry (DXA) while reducing fracture incidence in postmenopausal osteoporoticwomen. Changes in DXA BMD with ABL, 80 μg, were significantly greater than with open-label teriparatide (TPTD), 20 μg, at cortical sites including total hip, femoral neck, and 1/3 distal radius. The purpose of this study was to better understand the relative effects of ABL and TPTD on cortical and cancellous compartments in the proximal femur. METHODS:Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18. RESULTS: Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months. In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD. In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains. CONCLUSION: These results suggest previously reported differences in areal BMD increases between ABL and TPTD may be due to differential effects on cortical vBMD. Further studies are warranted to investigate how these differences affect therapeutic impact on hip strength in postmenopausal women with osteoporosis.
Authors: Paul D Miller; Gary Hattersley; Bente Juel Riis; Gregory C Williams; Edith Lau; Luis Augusto Russo; Peter Alexandersen; Cristiano A F Zerbini; Ming-yi Hu; Alan G Harris; Lorraine A Fitzpatrick; Felicia Cosman; Claus Christiansen Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: Masahiko Sato; Michael Westmore; Yanfei L Ma; Allen Schmidt; Qing Q Zeng; Emmett V Glass; John Vahle; Robert Brommage; Christopher P Jerome; Charles H Turner Journal: J Bone Miner Res Date: 2004-01-12 Impact factor: 6.741
Authors: N Doyle; A Varela; S Haile; R Guldberg; P J Kostenuik; M S Ominsky; S Y Smith; G Hattersley Journal: Osteoporos Int Date: 2017-12-19 Impact factor: 4.507
Authors: N B Watts; G Hattersley; L A Fitzpatrick; Y Wang; G C Williams; P D Miller; F Cosman Journal: Osteoporos Int Date: 2019-03-21 Impact factor: 4.507
Authors: Melanie Kistler-Fischbacher; Jedidah S Yong; Benjamin K Weeks; Belinda R Beck Journal: Calcif Tissue Int Date: 2022-06-12 Impact factor: 4.000
Authors: David W Dempster; Hua Zhou; Sudhaker D Rao; Chris Recknor; Paul D Miller; Benjamin Z Leder; Miriam Annett; Michael S Ominsky; Bruce H Mitlak Journal: J Bone Miner Res Date: 2021-01-28 Impact factor: 6.741